Osteoporosis management: translating research into optimal fracture protection II

References

• National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003
   Google Scholar
• Andrade SE, Majumdar SR, Chan KA, . Low frequency of treatment of osteoporosis among postmenopausal women following fracture. Arch Intern Med 2003; 163: 2052–57
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Rowe BH, Folk D, . A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 2004; 141: 366–73
   PubMed Web of Science ®Google Scholar
• Boonen S, Singer A. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture (part 1 of 2). Curr Med Res Opin 2008; 24: 1783–90
   Google Scholar
• Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005; 353: 595–603
   PubMed Web of Science ®Google Scholar
• Sanders KM, Nicholson GC, Watts JJ, . Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006; 38: 694–700
   Google Scholar
• World Health Organization. Prevention and management of osteoporosis. WHO Tech Rep Ser 2003; 921: 1–164
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721–39
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, . A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375–82
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, . Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320–3
   PubMed Web of Science ®Google Scholar
• Colón-Emeric C, Kuchibhatla M, Pieper C, . The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003; 14: 879–83
   PubMed Web of Science ®Google Scholar
• Hodgson SF, Watts NB, Bilezikian JP, . American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544–64
   PubMedGoogle Scholar
• Saag KG, Morgan SL, Coa X. Bone health and disease. Arthritis and Allied Conditions. A Textbook of Rheumatology, 15. Koopman WJ, Moreland LW, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2005: 2487
   Google Scholar
• National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
   Google Scholar
• Health US Department of and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004 Available at: www.hhs.gov/surgeongeneral/library/bonehealth/ [Last accessed 30 April 2007]
   Google Scholar
• Miller PD, Barlas S, Brenneman SK, . An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004; 164: 1113–20
   PubMed Web of Science ®Google Scholar
• Black DM, Steinbuch M, Palermo L, . An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519–28
   PubMed Web of Science ®Google Scholar
• The World Health Organization Fracture risk assessment tool. Available at www.shef.ac.uk/FRAX [Last accessed 26 February 2008]
   Google Scholar
• Kanis JA, Johnell O, Oden A, . FRAX™ and assessment of fracture probability in men and women from the UK. Osteoporos Int 2008. DOI 10.1007/s00198-007-0543-5
   Google Scholar
• Dawson-Hughes B, Tosteson ANA, MeltonIII LJ, . Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008. DOI 10.1007/s00198-008-0559-5
   Google Scholar
• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13: 340–67
   PubMed Web of Science ®Google Scholar
• Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119(4 Suppl 1):S25–31
   Google Scholar
• Watts NB, Geusens P, Barton IP, . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005; 20: 2097–104
   PubMed Web of Science ®Google Scholar
• Boonen S, Lips P, Bouillon R, . Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92: 1415–23
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–41
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–22
   PubMed Web of Science ®Google Scholar
• Chesnut 3rd CH, Skag A, Christiansen C, . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–9
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, . Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20: 433–9
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, . Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: 129–35
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, . Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118–24
   PubMed Web of Science ®Google Scholar
• Pols HA, Felsenberg D, Hanley DA, . Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461–8
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Miller P, Armbrecht G, . Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone 2005; 37: 651–4
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280: 2077–82
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colón-Emeric CS, Magaziner JS, . Zoledronic acid and clinical fractures and mortality after hip fracture. HORIZON Recurrent Fracture Trial. N Engl J Med 2007; 357: 1799–809
   PubMed Web of Science ®Google Scholar
• Watts NB, Worley K, Solis A, . Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004; 10: 142–51
   PubMedGoogle Scholar
• Silverman SL, Watts NB, Delmas PD, . Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18: 25–34
   PubMed Web of Science ®Google Scholar
• Motheral BR, Fairman KA. The use of claim databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997; 19: 346–66
   PubMed Web of Science ®Google Scholar
• Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000; 11: 533–6
   PubMed Web of Science ®Google Scholar
• Dunford J, Thompson K, Coxon FP, . Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235–42
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ, . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617–27
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Grove MR, Hammond CS, . Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209–16
   PubMed Web of Science ®Google Scholar
• Fosamax® (alendronate sodium) prescribing information. Whitehouse Station, NJ: Merck & Co., Inc., May 2007 Available at: www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf [Last accessed 8 November 2007]
   Google Scholar
• Actonel® (risedronate sodium) prescribing information. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc., May 2007 Available at: www.actonel.com/global/prescribing_information_aug.pdf [Last accessed 8 November 2007]
   Google Scholar
• Boniva® (ibandronate sodium) prescribing information. Nutley, NJ: Roche Laboratories Inc., August 2006. Available at: www.rocheusa.com/products/Boniva/PI.pdf [Last accessed April 30 2007]
   Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753–61
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479–91
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013–22
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, . Compliance and persistence with bisphosphonates dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–60
   PubMed Web of Science ®Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006; 22: 2383–91
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O, . Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17: 914–21
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterinen K, . Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895–903
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, . A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 28: 1023–31
   Google Scholar
• Delmas PD, Benhamou CL, Man Z, . Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos IntDec 182007. [Epub ahead of print]
   Web of Science ®Google Scholar
• Delmas PD, McClung MR, Zanchetta JR, . Efficacy and safety of Risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008; 42: 36–42
   PubMed Web of Science ®Google Scholar
• Reclastl® (zoledronic acid) prescribing information. Novartis Pharma Stein AG. Stein, Switzerland. Available at: www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf [Last accessed 25 February 2008]
   Google Scholar
• Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 2006; 17: 29–40
   PubMed Web of Science ®Google Scholar
• Ström O, Borgström F, Sen SS, . Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries – an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18: 1047–61
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, Johnell O, . Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15: 862–71
   PubMed Web of Science ®Google Scholar
• Brixner D. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Manag Care 2006; 12: S191–8
   PubMed Web of Science ®Google Scholar
• Jansen JP, Gaugris S, Bergman G, . Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res OpinJan 242008. [Epub ahead of print]
   Web of Science ®Google Scholar